Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Someone mention Halozyme and the good success they had against pancreatic cancer.

Again, I am far from a Doctor, but from what I understand, Halozyme doesn't make a "medicine" that cures or does anything for cancer. They make a "medicine" that may help other actual cancer medicines work better.

They have an enzyme (rHuPH20) that degrades hyaluronan.
The hyaluronan degradation leads to reduced tumor pressure, restores blood flow and aids the circulation of co-administered anti-cancer therapies.

They are using their enzyme along with both ABRAXANE and Gemcitabine.

Results:
All 60 patients are evaluable for safety and efficacy. Two (3%) grade 3/4 TE events occurred (one in each cohort), and two grade 3 GI hemorrhages; these AEs resolved with supportive treatment. There were three (5%) complete responses, 28 (47%) partial responses, 20 (33%) stable disease responses, and 9 (15%) progressive disease/non-evaluable responses. Median PFS is 7.0 months across both cohorts, and median overall survival has not been reached.

MultiTAA may become a first line treatment by itself, a stand alone treatment, a follow up treatment after other therapies.

Whereas Halozyme is trying to make 2 older medicines from 2005 + 2013 work better.

Glad they had the success they did but I don't really think they are in the same ballpark as the potential that MultiTAA has.